Download PDF
Nuklearmedizin 2010; 49(01): N2-N3
DOI: 10.1055/s-0038-1626486
Case report
Schattauer GmbH

Intraarterial 131I-MIBG therapy of neuroendocrine tumours with liver metastases

M. Popp
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Dresden, Germany
,
A. Strumpf
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Dresden, Germany
,
K. Zöphel
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Dresden, Germany
2   ZIK OncoRay, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Germany
,
C. Stroszczynski
3   Institut und Poliklinik für Radiologische Diagnostik, Universitätsklinikum Dresden, Germany
,
J. Kotzerke
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Dresden, Germany
2   ZIK OncoRay, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Germany
› Author Affiliations
Further Information

Publication History

Received: 10 November 2009

accepted in revised form: 10 December 2009

Publication Date:
25 January 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Bestagno M, Pizzocaro C, Pagliaini R. et al. Results of [131I]metaiodobenzylguanidine treatment in metastatic carcinoid. J Nucl Biol Med 1991; 35: 343-345.
    Google Scholar
  • 2 Bomanji JB, Wong W, Gaze MN. et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003; 15: 193-198.
    CrossrefGoogle Scholar
  • 3 Brogsitter C, Pinkert J, Bredow J. et al. Enhanced tumor uptake in neuroendocrine tumors after in- traarterial application of 131I-MIBG. J Nucl Med 2005; 46: 2112-2116.
    Google Scholar
  • 4 Fischer M. Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine. J Nucl Biol Med 1991; 35: 292-294.
    Google Scholar
  • 5 Giammarile F, Chiti A, Lassmann M. et al. EANM procedure guidelines for 131I-meta-iodobenzyl- guanidine therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1039-1047.
    CrossrefGoogle Scholar
  • 6 Hendlisz A, Flamen P, Van den Eynde M. et al. Locoregional and radioisotopic targeted treatment of neuroendocrine tumours. Acta Gastroenterol Belg 2009; 72: 44-48.
    Google Scholar
  • 7 Hoefnagel CA, De Kraker J, Valdes Olmos RA, Voute PA. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 1994; 15: 712-717.
    CrossrefGoogle Scholar
  • 8 Hoefnagel CA, Taal BG, Sivro F. et al. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun 2000; 21: 755-761.
    CrossrefGoogle Scholar
  • 9 Tavris DR, Dey S, Albrecht-Gallauresi B. et al. Risk of local adverse events following cardiac catheterization by hemostasis device use - phase II. J Invasive Cardiol 2005; 17: 644-650.
    Google Scholar